SecBot SecBot
SECBOTREPLAY Home › Report › UTMD

UTMD · UTMD reported Q2 2026 revenue of $8.5M, down 14.3% YoY, and EPS of…

UTAH MEDICAL PRODUCTS INC · 8-K filed Jul 23, 2026 at 15:13 ET

At the news

BEARISHIMPACT 7/10

8-K filed Jul 23, 2026 at 15:13 ET

UTMD reported Q2 2026 revenue of $8.5M, down 14.3% YoY, and EPS of $0.844, down 10.1% YoY, reflecting the continued loss of its two largest customers (PendoTECH and China distributor). Management lowered full-year 2026 revenue guidance to a 10-13% decline from prior expectations of flat sales, as new product sales to biopharma customers have been slower than anticipated. The balance sheet remains debt-free with $87.5M cash, but the top-line trajectory and guidance cut signal ongoing headwinds.

  • Q2 2026 revenue fell 14.3% to $8.53M vs $9.95M in Q2 2025; EPS declined 10.1% to $0.844 from $0.939
  • Full-year 2026 revenue guidance lowered to a 10-13% decline (from prior expectation of flat vs 2025) due to slower-than-expected new product sales
  • Loss of two former largest customers (PendoTECH OEM and China distributor) accounted for 75% of the Q2 revenue decline
  • Litigation expense guidance raised: 2026 now expected to be less than $1.6M (vs $1.355M in 2025), reversing prior expectation of a decline

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access